Pioglitazone

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Kidney, European Commission, Diabetes, INN, Risk, Allergy, ATC, Hypoglycemia, Hormone, International, Diet, Pancreas, European, Insulin, Metformin, Disease, Blood, Language, Glycated hemoglobin, DPP-4, Glucose, Type, Tablet, Select, Committee, Patient, Safety, Pioglitazone, Anatomy, Medicine, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

AI Revolutionizes Non-Alcoholic Steatohepatitis (NASH) Diagnosis and Treatment, Fueling Impressive 53.49% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Health, Pharmaceutical, Stroke, Mayo Collaborative Services v. Prometheus Laboratories, Inc., AstraZeneca, Incidence, Compound annual growth rate, Liver, Therapy, Vitamin E, Cirrhosis, Medicine, Prevalence, Conditional sentence, ONE, Vitamin, Inflammation, Exercise, Hepatitis, Drug development, Non-alcoholic fatty liver disease, NASH, Clinical trial, Liver cancer, COVID-19, Risk, Novartis, Pharmacy, NAFLD, Cell damage, Diagnosis, Intercept Pharmaceuticals, Pharmaceutical industry, Dietary supplement, Medical device, Others, Pioglitazone

The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.

Key Points: 
  • The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.
  • NASH, often referred to as "Silent Liver Disease," is a liver disorder caused by long-term alcohol abuse but mainly impacts non-alcoholics.
  • It is the second stage of Non-Alcoholic Fatty Liver Disease (NAFLD), marked by liver inflammation and cell damage.
  • As a result, there was an increased demand for NASH treatment, diagnostic tools, and emerging drugs, positively impacting the market.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Adrenoleukodystrophy, Patient, Serono, ALD, Plasma, AMN, Patent, Biomarker, Sumitomo Pharma, Diabetes, Merck, SGLT2, Jaguar 3.4 Litre, EPO, Pharmacokinetics, Male, DPP4, Disease, Prescription, Marshal of France, Pioglitazone, European Patent Office, EUR, United States patent law, Merck Serono, VLCFA, Safety, European Patent Convention, JPY, Estonia, Kidney, POC, Pharmaceutical industry, Imeglimin

Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.

Key Points: 
  • Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Diabetes, ULF, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, Sumitomo Pharma, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, AMN, IRIS, Scientific communication, United States patent law, SGLT2, VLCFA, EUR, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Imeglimin, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.

Attorney R. Brent Wisner Recognized in 2023 Top 100 Lawyers and Class Action-Mass Tort Trailblazers

Retrieved on: 
Tuesday, September 12, 2023
Takeda Pharmaceutical Company, Cancer, Lawyer, Bladder cancer, Negotiation, RICO, Racketeer Influenced and Corrupt Organizations Act, Daily Journal Corporation, Risk, Daily Journal, Eli Lilly and Company, The National Law Journal, Pharmaceutical industry, Tobacco, Pioglitazone

LOS ANGELES, Sept. 12, 2023 /PRNewswire/ -- Wisner Baum's managing partner and senior trial attorney, R. Brent Wisner, has been recognized in the Daily Journal's Top 100 Lawyers and the National Law Journal's Class Action | Mass Tort Litigation Trailblazers for 2023.

Key Points: 
  • LOS ANGELES, Sept. 12, 2023 /PRNewswire/ -- Wisner Baum's managing partner and senior trial attorney, R. Brent Wisner, has been recognized in the Daily Journal's Top 100 Lawyers and the National Law Journal's Class Action | Mass Tort Litigation Trailblazers for 2023.
  • Plaintiff James Goetz would have been the first of many thousands of claimants to allege Zantac causes cancer before a jury.
  • Instead, the next Zantac trial will take place this November, with Wisner serving as co-lead trial counsel alongside Jennifer Moore of the Moore Law Group.
  • Wisner and Moore serve as co-lead trial counsel in both state court litigations.

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Kinarus Therapeutics Announces Personnel Changes

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics Announces Personnel Change

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.